

FORM PTO-1390 (Modified)
(REV. 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

A34454-PCT-USA

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/889812

INTERNATIONAL APPLICATION NO.

PCT/GB00/00146

INTERNATIONAL FILING DATE

20 January 2000

PRIORITY DATE CLAIMED

22 January 1999

TITLE OF INVENTION

A METHOD OF DNA SEQUENCING

APPLICANT(S) FOR DO/EO/US

RONAGHI, Mostafa

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Form PCT/IB/332, a marked-up version of the amended claims, a postcard and a check in the amount of \$1,126.

Express Mail Label No.: EK839854832US

Date of Deposit: 20 July 2001

APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

09/889812

PCT/GB00/00146

A34454-PCT-USA

20. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Search Report has been prepared by the EPO or JPO \$840.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00
- ☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00
- ☒ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00

CALCULATIONS PTO USE ONLY

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$970.00

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

☐ 20 ☐ 30

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	14 - 20 =	0	x \$18.00	\$0.00
Independent claims	5 - 3 =	2	x \$78.00	\$156.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00

TOTAL OF ABOVE CALCULATIONS = \$1,126.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

☐

\$0.00

SUBTOTAL = \$1,126.00

Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).

☐ 20 ☐ 30

\$0.00

TOTAL NATIONAL FEE = \$1,126.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☐

\$0.00

TOTAL FEES ENCLOSED = \$1,126.00

Amount to be:	\$
refunded	
charged	\$

- ☒ A check in the amount of **\$1,204.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **02-4377** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

LOUIS S. SORELL
Baker Botts LLP
30 Rockefeller Plaza
New York, NY 10112-0228

SIGNATURE

Janet M. MacLeod

NAME

35,263

REGISTRATION NUMBER

20 July 2001

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : RONAGHI, Mostafa
Serial No. : To be assigned
Filed : 20 January 2000
For : A METHOD OF DNA SEQUENCING

Express Mail Label No. EK839854832US

PRELIMINARY AMENDMENT

Assistant Commissioner of Patent
Box PCT
Washington, D.C., 20231

Sir or Madam:

Prior to examination of the above-identified application, please make the following amendments:

IN THE CLAIMS:

Please cancel Claim 11 without prejudice.

Please amend the following claims:

Claim 4, Line 1: please delete "any of the preceding claims" and
substitute --claim 1-- .

Claim 5, Line 1: please delete "any of the preceding claims" and
substitute --claim 1-- .

Claim 6, Line 1: please delete "any of the preceding claims" and
substitute --claim 1-- .

Claim 8, Line 1: please delete "any of the preceding claims" and
substitute --claim 1-- .

Claim 9, Lines 1-2: please delete "any of the preceding claims" and substitute --claim 1-- .

Claim 10, Lines 1-2: please delete "any of the preceding claims" and substitute --claim 1-- .


REMARKS

The application has been amended to delete a "use" style claim and to remove multiple claim dependencies. No new matter has been introduced by this amendment. Attached hereto is a page containing a marked-up version of the amended claims.

Favorable consideration and allowance of all pending claims is earnestly solicited.

Respectfully submitted,
BAKER BOTTS LLP

Dated: July 19, 2001


Louis S. Sorell
Reg. No. 32,439

Janet M. MacLeod
Reg. No. 35,263

Attorneys for the Applicant
Tel. (212) 408-2500

Enclosure

BAKER BOTTS L.L.P. ■
30 Rockefeller Plaza
New York, New York 10112-0228
212.408.2500
FAX 212.705-5020

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claim 11 has been canceled without prejudice.

Claims 4-6 and 8-10 have been amended as follows:

4. (Amended) A method as claimed in [any of the preceding claims] claim 1 wherein the sample nucleic acid is DNA.
5. (Amended) A method as claimed in [any of the preceding claims] claim 1 wherein the single-stranded nucleic acid binding protein binds to the sample nucleic acid.
6. (Amended) A method as claimed in [any of the preceding claims] claim 1 wherein the incorporation of the nucleotide is detected by monitoring the release of inorganic pyrophosphate.
8. (Amended) A method as claimed in [any of the preceding claims] claim 1 wherein the apyrase is present during the polymerase reaction.
9. (Amended) A as claimed in [any one of the preceding claims] claim 1 wherein the single-stranded nucleic acid binding protein is added after hybridisation of the primer to the sample nucleic acid.
10. (Amended) A method as claimed in [any one of the preceding claims] claim 1 wherein at least 25 bases in the nucleic acid sample are identified.

A method of DNA sequencing

The present invention relates to methods of nucleic acid sequencing and in particular to sequencing-by-synthesis methods, ie. those methods based on the detection of nucleotide incorporation during polymerase extension, rather than on analysis of the nucleotide sequence itself, and to the improvements derivable in such methods by the use of a single-stranded DNA binding protein.

DNA sequencing is an essential tool in molecular genetic analysis. The ability to determine DNA nucleotide sequences has become increasingly important as efforts have commenced to determine the sequences of the large genomes of humans and other higher organisms. The two most commonly used methods for DNA sequencing are the enzymatic chain-termination method of Sanger and the chemical cleavage technique of Maxam and Gilbert. Both methods rely on gel electrophoresis to resolve, according to their size, DNA fragments produced from a larger DNA segment. Since the electrophoresis step as well as the subsequent detection of the separated DNA-fragments are cumbersome procedures, a great effort has been made to automate these steps. However, despite the fact that automated electrophoresis units are commercially available, electrophoresis is not well suited for large-scale genome projects or clinical sequencing where relatively cost-effective units with high throughput are needed. Thus, the need for non-electrophoretic methods for sequencing is great and several alternative strategies have been described, such as scanning tunnel electron microscopy (Driscoll et al., 1990, Nature, 346, 294-296), sequencing by hybridization (Bains et al., 1988, J. Theo. Biol. 135, 308-307) and single molecule detection (Jeff et al., 1989, Biomol.

Struct. Dynamics, 7, 301-306), to overcome the disadvantages of electrophoresis.

Techniques enabling the rapid detection of a single DNA base change are also important tools for genetic analysis. In many cases detection of a single base or a few bases would be a great help in genetic analysis since several genetic diseases and certain cancers are related to minor mutations.

Sequencing-by-synthesis methods are useful ways of determining the sequence of a DNA molecule of up to a hundred or more bases or the identity of a single nucleotide within a sample DNA molecule. During typical sequencing-by-synthesis methods the four different nucleotides (adenine, thymine, guanine and cytosine) are conveniently added cyclically in a specific order; when the base which forms a pair (according to the normal rules of base pairing, A-T and C-G) with the next base in the single-strand target sequence is added, it will be incorporated into the growing complementary strand by a polymerase and this incorporation will trigger a detectable signal. The event of incorporation can be detected directly or indirectly. In direct detection, nucleotides are usually fluorescently labelled allowing analysis by a fluorometer. (US Patent 48638449, US Patent 5302509, Metzker et al. Nucl. Acids Res. (1994) 22: 4259-4267, Rosenthal International Patent Application No. WO 93/213401, WO 91/06678, Canard et al. Gene (1994) 148: 1-6). One such strategy of sequencing-by-synthesis called base addition sequencing scheme (BASS) is based on nucleotide analogues that terminate DNA synthesis. BASS involves repetitive cycles of incorporation of each successive nucleotide, *in situ* monitoring to identify the incorporated base, and deprotection to allow the next cycle of DNA synthesis. Indirect detection usually takes advantage of enzymatic detection, e.g. measuring the release of PPi (inorganic pyrophosphate) during a polymerization

reaction (WO 93/23564 and WO 89/09283). As each nucleotide is added to a growing nucleic acid strand during a polymerase reaction, a pyrophosphate molecule is released. It has been found that pyrophosphate released under these conditions can be detected enzymatically e.g. by the generation of light in the luciferase-luciferin reaction. Such methods enable a base to be identified in a target position and DNA to be sequenced simply and rapidly whilst avoiding the need for electrophoresis and the use of harmful radiolabels. These methods based on release of PPI are referred to herein as Pyrosequencing. The basic PPI-based sequencing methods have been improved by using a dATP analogue in place of dATP (WO 98/13523) and including a nucleotide-degrading enzyme such as apyrase during the polymerase reaction step, so that unincorporated nucleotides are degraded, as described in WO 98/28440.

However, these sequencing-by-synthesis methods mentioned above are not without drawbacks. A particular problem arises when the DNA to be sequenced has a number of identical adjacent bases, especially 3 or more the same. Figure 1 shows the trace obtained when a single-stranded PCR product is sequenced according to known sequencing-by-synthesis methods (in this case involving detection of PPI). Figure 1 shows that known methods do not provide clear results when two or more adjacent bases in the sample molecule are the same. For example, the peak height when the first set of three adenine residues are incorporated is almost the same as when four thymine residues are incorporated later; the set of three adenine residues incorporated around the middle of the sequence have the same peak height as previous doublets and the last pair of adenine residues to be incorporated have a peak height corresponding to single bases from the earlier part of the sequence.

Other problems of sequencing-by-synthesis methods include false signals which are the result of

mispriming, i.e. hybridisation of the primer not to its targeted complement within the target DNA sequence but to another region which will result in generation of "incorporation signals" which do not reflect the identity of the target sequence. There is an associated problem which can result in a false indication of incorporation termed "minus frame incorporation", where a proportion of the growing primer originating strands are not fully extended and false positive signals appear in subsequent cycles.

Thus, there is a need further to improve sequencing-by-synthesis methods by addressing the above problems and more generally to improve the accuracy of the methods while providing methods which are simple and quick to perform, lending themselves readily to automation.

It has surprisingly been found that including a single-stranded nucleic acid binding protein in the reaction mixture improves the ratio of signals generated by one, two, three or more adjacent bases and reduces the number of false signals and generally improves the efficacy and reduces the cost of sequencing-by-synthesis methods.

In one aspect, the present invention thus provides a method of identifying a base at a target position in a sample nucleic acid sequence wherein a primer, which hybridises to the sample nucleic acid immediately adjacent to the target position, is provided and the sample nucleic acid and primer are subjected to a polymerase reaction in the presence of a nucleotide whereby the nucleotide will only become incorporated if it is complementary to the base in the target position, and said incorporation is detected, characterised in that, a single-stranded nucleic acid binding protein is included in the polymerase reaction step.

The nucleic acid to be sequenced may be any nucleotide sequence it is desirable to obtain sequence

information about. Thus, it may be any polynucleotide, or indeed oligonucleotide sequence. The nucleic acid may be DNA or RNA, and may be natural, isolated or synthetic. Thus, the target DNA may be genomic DNA, or cDNA, or a PCR product or other amplicon etc. Alternatively, the target DNA may be synthetic, and genomic DNA, cDNA or a PCR product etc. may be used as primer. The target (sample) nucleic acid may be used in any convenient form, according to techniques known in the art e.g. isolated, cloned, amplified etc., and may be prepared for the sequencing reaction, as desired, according to techniques known in the art.

The DNA may also be single or double-stranded - whilst a single-stranded DNA template has traditionally been used in sequencing reactions, or indeed in any primer-extension reaction, it is possible to use a double-stranded template; strand displacement, or a localised opening-up of the two DNA strands may take place to allow primer hybridisation and polymerase action to occur.

The sample nucleic acid acts as a template for possible polymerase based extension of the primer and thus may conveniently be referred to as "template" or "nucleic acid template".

In the polymerase reaction, any convenient polymerase enzyme may be used according to choice, as will be described in more detail below. In the case of a RNA template, such a polymerase enzyme may be a reverse transcriptase enzyme. The nucleotide may be any nucleotide suitable for a polymerase chain extension reaction e.g. a deoxynucleotide or a dideoxynucleotide. The nucleotide may optionally be labelled in order to aid or facilitate detection of nucleotide incorporation. One or more nucleotides may be used.

Nucleotide incorporation by the action of the polymerase enzyme may be detected directly or indirectly, and methods for this are well known in the

art. Representative methods are described for example in US-A-4,863,879 of Melamede. As mentioned above, detection of incorporation may be by means of labelled nucleotides, for example fluorescently labelled nucleotides, as is well known in sequencing procedures known in the art. Alternatively, the event of incorporation may be detected by other means e.g. indirectly. Detection of incorporation also includes the detection of absence of incorporation e.g. lack of a signal. Thus, it may be detected whether or not nucleotide incorporation takes place.

The method of the invention thus has utility in a number of different sequencing methods and formats, including mini-sequencing procedures e.g. detection of single base changes (for example, in detecting point mutations, or polymorphisms, or allelic variations etc). The method of the invention may thus be used in a "full" sequencing procedure, ie. the identification of the sequential order of the bases in a stretch of nucleotides, as well in single base detection procedures.

For example, to determine sequence information in a target nucleotide sequence, different deoxynucleotides or dideoxynucleotides may be added either to separate aliquots of sample-primer mixture or successively to the same sample-primer mixture and subjected to the polymerase reaction to indicate which deoxynucleotide or dideoxynucleotide is incorporated.

In order to sequence the target DNA, the procedure may be repeated one or more times i.e. cyclically, as is known in the art. In this way the identity of many bases in the sample nucleic acid may be identified, essentially in the same reaction.

Hence, a sequencing protocol may involve annealing a primer as described above, performing a polymerase-catalysed primer extension step, detecting the presence or absence of incorporation, and repeating the

nucleotide addition and primer extension steps etc. one or more times. As discussed above, nucleotides may be added singly or individually, or in a mixture, successively to the same primer-template mixture, or to separate aliquots of primer-template mixture, or to separate aliquots of primer-template mixture etc. according to choice, and the sequence information it is desired to obtain.

The term "single-stranded nucleic acid binding protein" as used herein is intended to refer to the class of proteins collectively referred to by the term SSB (Ann. Rev. Biochem. [1986] 55 103-136 Chase et al.). SSB has the general property of preferential binding to single-stranded (ss) over double-stranded (ds) nucleic acid molecules. The class includes *E. coli* single-stranded binding protein (Eco SSB), T4 gene 32 protein (T4 gp32), T7 SSB, coliphage N4 SSB, T4 gene 44/62 protein, adenovirus DNA binding protein (AdDBP or AdSSB), calf thymus unwinding protein (UP1) and the like (Coleman et al. CRC Critical Reviews in Biochemistry, (1980) 7(3), 247-289 and p5 SSB from fi-29 DNA (Lindberg et al. J. Biol. Chem. (1989) 264 12700-08) (Nakashima et al. FEBS Lett. (1974) 43 125). Any functionally equivalent or analogous protein, for example derivatives or modifications of the above-mentioned proteins, may also be used. Eco SSB or derivatives thereof are particularly preferred for use in the methods of the present invention.

Thus, modified single-stranded nucleic acid binding proteins derived by isolation of mutants or by manipulation of cloned single-stranded nucleic acid binding proteins which maintain the advantageous properties described herein, are also contemplated for use in the methods of the invention.

The term "dideoxynucleotide" as used herein includes all 2'-deoxynucleotides in which the 3'-hydroxyl group is absent or modified and thus, while

able to be added to the primer in the presence of the polymerase, is unable to enter into a subsequent polymerisation reaction.

As described above, the method of the invention may be performed in a number of ways, and has utility in a variety of sequencing protocols. Viewed more generally, the present invention can thus be seen to provide the use of a single-stranded nucleic acid binding protein in a nucleic acid sequencing-by-synthesis method. In particular, the single-stranded nucleic acid binding protein is used to bind to the nucleic acid template.

What is meant by a DNA sequencing-by-synthesis method is defined above, namely that sequence information is derived by detecting incorporation of a nucleotide in a primer extension reaction. As explained above, such sequencing-by-synthesis protocols, include not only "full" sequencing methods, but also mini-sequencing methods etc., yielding more limited sequence information.


Any sequencing-by-synthesis method, as described above, is suitable for use in the methods of the present invention but methods which rely on monitoring the release of inorganic pyrophosphate (PPi) are particularly preferred. In this case, incorporation of the nucleotide will be measured indirectly by enzymatic detection of released PPi.

PPi can be determined by many different methods and a number of enzymatic methods have been described in the literature (Reeves et al., (1969), Anal. Biochem., 28, 282-287; Guillory et al., (1971), Anal. Biochem., 39, 170-180; Johnson et al., (1968), Anal. Biochem., 15, 273; Cook et al., (1978), Anal. Biochem. 91, 557-565; and Drake et al., (1979), Anal. Biochem. 94, 117-120).

It is preferred to use luciferase and luciferin in combination to identify the release of pyrophosphate since the amount of light generated is substantially proportional to the amount of pyrophosphate released

which, in turn, is directly proportional to the amount of base incorporated. The amount of light can readily be estimated by a suitable light sensitive device such as a luminometer.

Luciferin-luciferase reactions to detect the release of PPi are well known in the art. In particular, a method for continuous monitoring of PPi release based on the enzymes ATP sulphurylase and luciferase has been developed by Nyren and Lundin (Anal. Biochem., 151, 504-509, 1985) and termed ELIDA (Enzymatic Luminometric Inorganic Pyrophosphate Detection Assay). The use of the ELIDA method to detect PPi is preferred according to the present invention. The method may however be modified, for example by the use of a more thermostable luciferase (Kaliyama et al., 1994, Biosci. Biotech. Biochem., 58, 1170-1171). This method is based on the following reactions:



(APS = adenosine 5'-phosphosulphate)

The preferred detection enzymes involved in the PPi detection reaction are thus ATP sulphurylase and luciferase. Methods of detecting the light emitted are well known in the art.

In order to repeat the method cyclically and thereby sequence the sample nucleic acid and, also to aid separation of a single-stranded sample DNA from its complementary strand, it may be desirable that sample nucleic acid (DNA) is immobilised or provided with means for immobilisation attachment to a solid support.

Moreover, the amount of sample nucleic acid available may be small and it may therefore be desirable to amplify the sample nucleic acid before carrying out the method according to the invention.

The sample DNA may be amplified, for example *in vitro* by PCR, Self Sustained Sequence Replication (3SR), Rolling Circle Amplification or Replication (RCA or RCR), or indeed any other *in vitro* amplification technique, or *in vivo* using a vector and, if desired, *in vitro* and *in vivo* amplification may be used in combination. Whichever method of amplification is used, it may be convenient to adapt the method such that the amplified nucleic acid becomes immobilised or is provided with means for attachment to a solid support. For example, a PCR primer may be immobilised or be provided with means for attachment to a solid support. Also, a vector may comprise means for attachment to a solid support adjacent the site of insertion of the sample DNA such that the amplified sample DNA and the means for attachment may be excised together.

Immobilisation of the amplified DNA may take place as part of the amplification itself, e.g. in PCR where one or more primers are attached to a support, or alternatively one or more of the primers may carry means for immobilisation e.g. a functional group permitting subsequent immobilisation, e.g. a biotin or thiol group. Immobilisation by the 5' end of a primer allows the strand of DNA emanating from that primer to be attached to a solid support and have its 3' end remote from the support and available for subsequent hybridisation with the extension primer and chain extension by polymerase.

The solid support may conveniently take the form of microtitre wells, or dipsticks which may be made of polystyrene activated to bind the primer DNA (K Almer, Doctoral Theses, Royal Institute of Technology, Stockholm, Sweden, 1988). However, any solid support may conveniently be used, including any of the vast

number described in the art, e.g. for separation/immobilisation reactions or solid phase assays. Thus, the support may also comprise particles, fibres or capillaries made, for example, of any polymer, e.g. agarose, cellulose, alginate, Teflon or polystyrene. Glass solid supports can also be used, e.g. glass plates or capillaries. Magnetic particles e.g. the superparamagnetic beads produced by Dynal AS (Oslo, Norway) are a preferred support since they can be readily isolated from a reaction mixture yet have superior reaction kinetics over many other forms of support.

The solid support may carry functional groups such as hydroxyl, carboxyl, aldehyde or amino groups, or other moieties such as avidin or streptavidin, for the attachment of primers or the target nucleic acid. These may in general be provided by treating the support to provide a surface coating of a polymer carrying one of such functional groups, e.g. polyurethane together with a polyglycol to provide hydroxyl groups, or a cellulose derivative to provide hydroxyl groups, a polymer or copolymer of acrylic acid or methacrylic acid to provide carboxyl groups or an aminoalkylated polymer to provide amino groups. Sulphur and epoxy-based functional groups may also be used. US Patent No. 4654267 describes the introduction of many such surface coatings.

The assay technique is very simple and rapid, thus making it easy to automate by using a robot apparatus where a large number of samples may be rapidly analysed. Since the preferred detection and quantification is based on a luminometric reaction this can be easily followed spectrophotometrically. The use of luminometers is well known in the art and described in the literature.

As mentioned above, the sample nucleic acid, i.e. the target nucleic acid to be sequenced, may be any nucleotide sequence, however obtained according to

techniques known in the art, e.g. cloning, DNA isolation etc. It may for example be cDNA synthesised from RNA in the sample and the method of the invention is thus applicable to diagnosis on the basis of characteristic RNA. Such preliminary synthesis can be carried out by a preliminary treatment with a reverse transcriptase, conveniently in the same system of buffers and bases of subsequent amplification e.g. PCR steps, if used. Since the PCR procedure requires heating to effect strand separation, in the case of PCR the reverse transcriptase will be inactivated in the first PCR cycle. When mRNA is the sample nucleic acid, it may be advantageous to submit the initial sample, e.g. a serum sample, to treatment with an immobilised polydT oligonucleotide in order to retrieve all mRNA via the terminal polyA sequences thereof. Alternatively, a specific oligonucleotide sequence may be used to retrieve the RNA via a specific RNA sequence. The oligonucleotide can then serve as a primer for cDNA synthesis, as described in WO 89/0982.

Advantageously, the primer for the polymerase chain extension step (ie., the extension primer) is sufficiently large to provide appropriate hybridisation with the sequence immediately 5' of the target position, yet still reasonably short in order to avoid unnecessary chemical synthesis. It will be clear to persons skilled in the art that the size of the extension primer and the stability of hybridisation will be dependent to some degree on the ratio of A-T to C-G base pairings, since more hydrogen bonding is available in a C-G pairing. Also, the skilled person will consider the degree of homology between the extension primer to other parts of the amplified sequence and choose the degree of stringency accordingly. Guidance for such routine experimentation can be found in the literature, for example, Molecular Cloning: a laboratory manual by Sambrook, J., Fritsch E.F. and Maniatis, T. (1989).

The primer is conveniently added before the sample is divided into (four) aliquots although it may be added separately to each aliquot. It should be noted that the extension primer may be identical with the PCR primer but advantageously it may be different, to introduce a further element of specificity into the system.

Where appropriate, the polymerase reaction is carried out using a polymerase which will incorporate deoxynucleotides and dideoxynucleotides, e.g. T7 polymerase, Klenow, ϕ 29 DNA polymerase or Sequenase Ver. 2.0 (USB U.S.A.). Any suitable polymerase may be used and many are known in the art and reported in the literature. However, it is known that many polymerases have a proof-reading or error checking ability and that 3' ends available for chain extension are sometimes digested by one or more nucleotides. If such digestion occurs in the method according to the invention the level of background noise increases. In order to avoid this potential problem, a nonproof-reading polymerase, e.g. T7 polymerase or Sequenase may be used. Otherwise it is desirable to add to each aliquot fluoride ions or nucleotide monophosphates which suppress 3' digestion by polymerase.

A fuller description of preferred embodiments of PPI based sequencing-by-synthesis methods are provided in WO 98/13523 and WO 98/28440 which are incorporated herein by reference. The use of a dATP analogue such as dATP α S in place of dATP is advantageous as it does not interfere with the detection reaction as it is capable of acting as a substrate for a polymerase but incapable of acting as a substrate for the PPI-detection enzyme luciferase. It is therefore possible to perform the chain extension and detection, or signal-generation, reactions substantially simultaneously by including the "detection enzymes" in the chain extension reaction mixture and therefore the sequencing reactions can be continuously monitored in real-time, with a signal being

generated and detected, as each nucleotide is incorporated.

Inclusion of a nucleotide degrading enzyme in the reaction mix is also advantageous as it means that it is not necessary to wash the template thoroughly between each nucleotide addition to remove all non-incorporated deoxynucleotides, which has the associated benefit that a template can be sequenced which is not bound to a solid support.

In a particularly preferred method of the invention, the nucleotide-degrading enzyme apyrase is included during the polymerase reaction step and it has been found that the single-stranded binding proteins used in the methods of the present invention are able to stimulate the activity of apyrase. Whilst not wishing to be bound by theory, it is believed that the "SSB" may play a role in reducing the inhibition of apyrase which may be observed in the presence of DNA.

Thus in a further aspect, the present invention provides a method of enhancing the activity of a nucleotide-degrading enzyme when used in a nucleic acid sequencing-by-synthesis method, which comprises the use of a single-stranded nucleic acid binding protein. More particularly, the methods comprise including or adding a single-stranded nucleic acid binding protein to the sequencing reaction mixture (i.e. the template, primer, polymerase and/or nucleotide (e.g.dNTP/ddNTP) mix).

A similar enhancing effect has been observed on the luciferase enzyme which may be used in signal detection and therefore in a further aspect the present invention provides a method of enhancing the activity of luciferase when used as a detection enzyme in a nucleic acid sequencing-by-synthesis method which comprises the use of a single-stranded nucleic acid binding protein. Again, such methods involve including or adding a single-stranded nucleic acid binding protein to the sequencing reaction mixture.

In a preferred embodiment of the present invention the single-stranded nucleic acid binding protein is added after hybridisation of the primer to the template nucleic acid molecule.

It is also preferred, not to remove the single-stranded nucleic acid binding protein after it has been added.

It is a particular advantage of the present sequencing methods that there need be no separation of the different reagents and enzymes involved in the extension and detection reactions but the labelled or unlabelled nucleotides or nucleotide analogues, sample, polymerase and where appropriate enzymes and enzyme substrates, as well as the single-stranded nucleic acid binding protein can be included in the reaction mixture and there is no need to remove the single-stranded nucleic acid binding protein for detection to take place.

The reaction mixture for the polymerase chain extension step may optionally include additional ingredients or components if desired. Thus, such additional components can include other substances or molecules which bind to DNA. Thus, amines such as spermidine may be used. It was observed that improved results may be obtained using spermidine in run-off extension reactions.

Alternative additional components include DNA binding proteins such as RecA. In particular, it has been observed that a synergy occurs between RecA and a single-stranded nucleic acid binding protein, leading to improved results. Accordingly, the combination of RecA with a single-stranded nucleic acid binding protein represents a preferred embodiment according to the present invention. Other DNA binding proteins involved in DNA replication, recombination, or structural organisation may also be used in similar manner.

Other components which may be included,

When a single strand nucleic acid binding protein is used in accordance with the methods of the present invention, the methods are robust and results are readily reproducible. The read-length, i.e. the length of nucleic acid which can be successfully sequenced, has been increased by four times as compared to previous sequencing-by-synthesis methods. The methods of the invention are suitable for midi-sequencing, ie. the sequencing of nucleic acid molecules having 9-50 bases, mini-sequencing, the detection of single bases such as SNPs (single nucleotide polymorphisms) responsible for genetic diseases and the sequencing of nucleic acid molecules of 100 bases or more. It is in the successful sequencing of larger molecules that the benefits of a single strand nucleic acid binding protein in, particularly PPI based, sequencing methods are observed. The problems of maintaining a constant signal intensity for incorporation of one nucleotide, two nucleotides and so on, throughout the whole sequencing run are overcome.

As well as increasing the read length, the use of a single stranded nucleic acid binding protein enables the use of longer template molecules. Thus, sequence information from e.g. a 50 base region within a template molecule of 400 or more bases can be obtained. Template molecules of 800 or more, even 1200 or 1500 or more bases can be used in the methods of the present invention.

The amount of sequencing template accessible for

the sequencing reaction may be reduced due to specific and/or unspecific interactions between the template and components of the reaction mixture and/or the surface of the vessel holding the reaction mixture. Such interaction may result in the reduction of the detected signal and/or generation of unspecific sequencing signal. SSB is believed to protect the template from such undesirable interactions and thus improve signal intensity and specificity. Furthermore, the protein may assist in "opening-up" and/or maintaining or stabilising the "open" structure of a double-stranded template.

When using the sequencing methods of the invention to detect mutations in a nucleic acid molecule, the sequencing reaction may advantageously be run bidirectionally to confirm the mutation.

Moreover, a further beneficial feature of the present invention is the stimulation of Klenow polymerase which is observable using the single-stranded nucleic acid binding protein according to the methods described herein.

Thus in a further aspect, the present invention provides a method of maintaining a constant signal intensity during a method of nucleic acid sequencing-by-synthesis comprising the use of a single-stranded nucleic acid binding protein. More particularly, the methods comprise including or adding a single-stranded nucleic acid binding protein to the sequencing reaction mixture (i.e. the template, primer, polymerase and/or nucleotide (e.g.dNTP/ddNTP) mix).

It is to be understood that 'constant signal intensity' in this context means that the strength of the signal, however measured, which indicates incorporation of the correct base-pair nucleotide remains substantially the same throughout the sequencing reaction, whether it is the first nucleotide incorporated, the twentieth or the sixtieth etc. Similarly, the strength of signal indicating

incorporation of two nucleotides (ie. two adjacent bases are the same in the molecule to be sequenced) remains constant throughout the whole sequencing reaction and so on for three bases, four bases etc.

The single-stranded nucleic acid binding protein is present in the 'reaction mixture', i.e. together with the reagents, enzymes, buffers, primer, sample etc. which may include a solid support and is the site of polymerisation and also, where appropriate, detection.

A further benefit of the use of a single-stranded nucleic acid binding protein in accordance with the present invention is the relatively small amount of sample nucleic acid which is required for generation of useful sequence information. Approximately 0.05 pmol DNA in a 50 μ l reaction is sufficient to obtain sequence information which means the quantity of enzymes needed for carrying out the extension reactions is less per cycle of nucleotide additions and per full sequencing reaction.

In a further aspect, the present invention provides a kit for use in a method of sequencing-by-synthesis which comprises nucleotides for incorporation, a polymerase, means (e.g. any reagents and enzymes needed) for detection of incorporation and a single-stranded nucleic acid binding protein.

The invention will now be described by way of non-limiting Examples with reference to the Figures in which:

Figure 1 shows a sequencing method of the prior art performed on a 130-base-long single-stranded PCR product hybridized to the sequencing primer. About 2 pmol of the template/primer was used in the assay. The reaction was started by the addition of 0.6 nmol of the indicated deoxynucleotide and the PPi released was detected. The DNA-sequence after the primer is indicated in the Figure.

Figure 2 shows Pyrosequencing of a PCR product a)

in the absence of a single-stranded DNA binding protein, b) in the presence of SSB from T4 phage (T4gp32), and c) in the presence of SSB from *E. coli*. Lower quality of sequence data is obtained in the absence of SSB as indicated by arrows.

Figure 3 shows a) the sequencing of mutated p53 template in the absence of a single strand DNA binding protein and b) sequencing of the same sequence when SSB is included.

Figure 4 shows a run off extension signal obtained on a 1500bp long PCR fragment using Klenow DNA polymerase. A) in the presence of SSB and B) in the absence of a single-stranded DNA binding protein.

Figure 5 shows the result of Pyrosequencing an 800bp long PCR template a) in the presence of SSB and b) in the absence of a single-stranded DNA binding protein.

Figure 6 shows, schematically, inhibition of apyrase in the presence of DNA and the ability of SSB to reduce the interaction of apyrase with the DNA.

Figure 7 shows the Pyrosequencing of a 450bp cDNA template A) in the absence of a single strand DNA binding protein and B) in the presence of SSB. The numbers underneath the peaks show the number of bases incorporated. In A) the dashed line indicates how the strength of signal which results from the incorporation of one base decreases as the sequencing reaction progresses. In B) the dashed lines indicate how the strength of signal as one or two bases are incorporated remains constant when the reaction is carried out in the presence of SSB.

EXAMPLE 1

Comparison of sequencing using *E. coli* SSB, SSB from T4 phage (T4gp32) and no SSB:

Pyrosequencing was performed on approximately 0.2 pmol of a 405-base-long single-stranded PCR product obtained

- 20 -

from mitochondrial DNA hybridised to 2 pmol of sequencing primer pH3A (5'-GCTGTACTTGCTTGTAAAGC). Primed DNA template together with 2 µg of SSB from *E. coli* (Amersham Pharmacia Biotech, Uppsala, Sweden) or 2 µg of T4gp32 (Amersham Pharmacia Biotech) was added to a four-enzyme-mixture comprising 6 U DNA polymerase (exonuclease-deficient Klenow DNA polymerase), 20 mM ATP sulfurylase, 200 ng firefly luciferase, and 50 mM apyrase.

The sequencing procedure was carried out by stepwise elongation of the primer-strand upon sequential addition of the different deoxynucleoside triphosphates (Pharmacia Biotech). The reaction was carried out at room temperature. Light was detected by a Pyrosequencer (Pyrosequencing AB, Uppsala, Sweden) as described by Ronaghi et al. (Science 1998, 281: 363-365). See Fig. 2. Unincorporated nucleotides were degraded by apyrase allowing sequential addition of the four different nucleotides in an iterative manner. For this Example the correct sequence is:
5'-AGCCCCACCCCCGGGGCAGCGCCAGG.

EXAMPLE 2

Detection of Mutations:

For mutation detection by Pyrosequencing, 2 pmol of primer COMP53 (5'-GCTATCTGAGCAGCGCTCA) was hybridised to the immobilised single-stranded PCR products obtained from exon 5 of p53 gene from normal and tumour tissues. 1/10 of the template obtained from a PCR product was used in a Pyrosequencing reaction and released light detected as described by Ronaghi et al. (Science 1998, 281: 363-365). There are two altered bases in the mutated template which can be seen by a signal corresponding to 1.5 bases for T, 0.5 bases for A and 1 base for G. See Fig. 3. The sequence for this Example is 5'-CAT(TA/GG)TGGGGG.

EXAMPLE 3**Stimulation by SSB of Klenow polymerase activity.**

A run off extension signal was obtained on a 1500 bp long PCR fragment using Klenow DNA polymerase in the presence of SSB and in the absence of SSB. PCR was performed on 16S rRNA gene with ENV1 (U1 universal primer *E. coli* positions 8-27) 5'-AGAGTTTGATITGGCTCAG and ENV2B (U8 universal primer *E. coli* positions 1515-1493) 5'-B-CGGITACCTTGTTACGACTT. After alkali treatment, the obtained single-stranded template (1/20 of a PCR product) was hybridised to 0.5 pmol of ENV1 primer for a run off extension reaction. 0.5 µg of *E. coli* SSB was added before extension using a coupled enzymatic reaction as described by Nyrén et al. (Anal. Biochem. 1997 244, 367-373). See Fig. 4.

EXAMPLE 4**Pyrosequencing of an 800 bp long PCR template in the presence of SSB, and in the absence of SSB.**

Pyrosequencing was performed on an 800-base-long single-stranded PCR product hybridised to the sequencing primer FSS-SEQ-DOWN(5'-CTGCTCGGGCCAGATCTG). Two µg of SSB from *E. coli* was added to the template/primer (1/5 of a PCR product in which 5 pmol of primers have been used for *in vitro* amplification) and the obtained complex was used in a Pyrosequencing reaction as described by Ronaghi et al. (Science 1998, 281: 363-365). The sequence obtained by Pyrosequencing using SSB is as follows: ATACGGTCCGGAATTC CGGTCGACCCACGCGCGGCCATCGCA CTTGCCCCACGTGTCGTTTTC). See Fig. 5.

EXAMPLE 5**Inhibition of apyrase by SSB in presence of DNA**

To a Pyrosequencing mixture containing 200 ng luciferase

and 50 mU apyrase, is added 4 pmol of ATP, and a signal is obtained. When the degradation curve reaches the base-line, 20 pmol of Romo70A (a 70-base-long oligonucleotide) is added to the solution (nucleotide degradation is inhibited 2.2 times by apyrase shown by a longer time needed to level off to the base line). When 2 μ g of SSB is added to the solution, the interaction of the apyrase with the DNA is diminished and apyrase freely functions in the solution and a similar signal as before oligonucleotide addition is obtained. Further addition of 4 pmol ATP shows approximately the same degradation rate as before oligonucleotide addition to the solution. SSB is thus effectively able to stimulate apyrase activity. See Fig. 6.

Example 6

Role of SSB in maintaining a constant signal during the sequencing reaction

Pyrosequencing of a 450 base-long cDNA template obtained by PCR using universal primers was performed in the absence of SSB, and in the presence of SSB. The 450bp single-stranded PCR product was hybridized to the sequencing primer FSS-SEQ-DOWN(5'-CTGCTCGGCCAGATCTG). 2 μ g of SSB from *E. coli* was added to the template/primer (1/5 of a PCR product in which 5 pmol of primers have been used for in vitro amplification) and the obtained complex was used in a Pyrosequencing reaction as described by Ronaghi et al. (Science 1998, 281:363-365). The sequence obtained by Pyrosequencing using SSB is: ATACCGGTCCGGAATCCCGGTCGACCCACGCA
See Fig. 7.

Claims

1. A method of identifying a base at a target position in a sample nucleic acid sequence wherein a primer, which hybridises to the sample nucleic acid immediately adjacent to the target position, is provided and the sample nucleic acid and primer are subjected to a polymerase reaction in the presence of a nucleotide whereby the nucleotide will only become incorporated if it is complementary to the base in the target position, and said incorporation is detected, characterised in that, a single-stranded nucleic acid binding protein is included in the polymerase reaction step.
2. A method as claimed in claim 1 wherein the single-stranded nucleic acid binding protein is selected from the group comprising *E. coli* single-stranded binding protein (Eco SSB), T4 gene 32 protein (T4 gp32), T7 SSB, coliphage N4 SSB, T4 gene 44/62 protein, adenovirus DNA binding protein (AdDBP or AdSSB) and calf thymus unwinding protein (UP1).
3. A method as claimed in claim 2 wherein the single-stranded nucleic acid binding protein is Eco SSB.
4. A method as claimed in any of the preceding claims wherein the sample nucleic acid is DNA.
5. A method as claimed in any of the preceding claims wherein the single-stranded nucleic acid binding protein binds to the sample nucleic acid.
6. A method as claimed in any of the preceding claims wherein the incorporation of the nucleotide is detected by monitoring the release of inorganic pyrophosphate.

7. A method as claimed in claim 6 wherein the release of inorganic pyrophosphate is detected using ATP sulphurylase and luciferase.
8. A method as claimed in any of the preceding claims wherein apyrase is present during the polymerase reaction.
9. A method as claimed in any one of the preceding claims wherein the single-stranded nucleic acid binding protein is added after hybridisation of the primer to the sample nucleic acid.
10. A method as claimed in any one of the preceding claims wherein at least 25 bases in the nucleic acid sample are identified.
11. Use of a single-stranded nucleic acid binding protein in a nucleic acid sequencing-by-synthesis method.
12. A method of enhancing the activity of a nucleotide-degrading enzyme when used in a nucleic acid sequencing-by-synthesis method, which comprises the use of a single-stranded nucleic acid binding protein.
13. A method of enhancing the activity of luciferase when used as a detection enzyme in a nucleic acid sequencing-by-synthesis method which comprises the use of a single-stranded nucleic acid binding protein.
14. A method of maintaining a constant signal intensity during a method of nucleic acid sequencing-by-synthesis comprising the use of a single-stranded nucleic acid binding protein.

- 25 -

15. A kit for use in a method of sequencing-by-synthesis which comprises nucleotides for incorporation, a polymerase, means for detection of incorporation and a single-stranded nucleic acid binding protein.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2




FIG. 1




FIG. 2






FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	RONAGHI	Group Art Unit: Examiner:
Appln. No.:	09/889,812	
File:	July 20, 2001	
Title:	A METHOD OF DNA SEQUENCING	

**DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION
(37 C.F.R. § 1.63)**

As a below named inventor, I hereby declare that my mailing address and citizenship are as stated below.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

A METHOD OF DNA SEQUENCING

the specification of which:

☐ is attached hereto OR

☒ was filed on July 20, 2001 as United States Application Number 09/889,812 and as PCT International Application Number PCT/GB00/00146 filed January 20, 2000 and amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information known to me that is material to patentability as defined in 37 C.F.R. 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				Yes	No
9901475.5	Great Britain	01/22/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. 120 of any earlier U.S./PCT application(s) listed below.

Application Serial Number(s)	Filing Date (MM/DD/YYYY)	Status (pending, patented, abandoned)

11-25-2001 01:10pm

From-STANFORD GENOME TECHNOLOGY CENTER

6809121975

T-640 P.004/006 F-282

POWER OF ATTORNEY

I hereby appoint Richard S. Clark, Reg. No. 26,154 and Janet M. MacLeod, Reg. No. 35,263, of the firm of Dorsey & Whitney LLP with offices at 250 Park Avenue, New York, New York 10177 as attorneys to prosecute the patent application identified above and to transact all business in the Patent and Trademark Office connected therewith, including full power of association, substitution, and revocation.

PLEASE DIRECT ALL CORRESPONDENCE TO:

Name	<u>Janet M. MacLeod</u>
Address	<u>DORSEY & WHITNEY LLP</u> <u>250 Park Avenue</u> <u>New York, NY 10177</u>
Telephone	<u>212-415-9200</u>
Fax	<u>212-953-7201</u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Sole or First Inventor:			
Given Name (First and middle)		Family Name or Surname	
<u>Mostafa</u>		<u>Rouaghi</u>	
Inventor's Signature	<u>Mostafa Rouaghi</u>		Date: <u>Nov. 126/2001</u>
Residence	<u>Palo Alto</u> <u>CA</u> <u>CA</u> <u>94304</u>	Citizenship: <u>Sweden</u>	
	City	State	Zip
Post Office Address	<u>Stanford DNA Sequencing & Technology Center, 855 California Avenue, Palo Alto, CA 94304</u>		

Second Inventor:			
Given Name (First and middle)		Family Name or Surname	
Inventor's Signature			Date:
Residence			Citizenship:
	City	State	Zip
Post Office Address			

Third Inventor:			
Given Name (First and middle)		Family Name or Surname	
Inventor's Signature			Date:
Residence			Citizenship:
	City	State	Zip
Post Office Address			

Fourth Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature		Date:	
Residence	City	State	Zip
Post Office Address		Citizenship:	

Fifth Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature		Date:	
Residence	City	State	Zip
Post Office Address		Citizenship:	

Sixth Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature		Date:	
Residence	City	State	Zip
Post Office Address		Citizenship:	

Seventh Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature		Date:	
Residence	City	State	Zip
Post Office Address		Citizenship:	

11-29-2001 01:11pm From:STANFORD GENOME TECHNOLOGY CENTER

6506121975

T-840 P.006/008 F-262

Eighth Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature			Date:
Residence	City	State	Zip
		Citizenship:	
Post Office Address			

Ninth Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature			Date:
Residence	City	State	Zip
		Citizenship:	
Post Office Address			

Tenth Inventor:

Given Name (First and middle)		Family Name or Surname	
Inventor's Signature			Date:
Residence	City	State	Zip
		Citizenship:	
Post Office Address			